Related Experiment Video
Updated: Aug 2, 2025
Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
Published on: August 25, 2023
Not all TMB assays are the same: Clinical validity of robust algorithmic germline filtering
Richard S P Huang1, Ryon P Graf1, Geoffrey R Oxnard1
1Foundation Medicine, Inc, Cambridge, MA, USA.
Abstract:
Huang et al. propose that a tumor-only calculation of tumor mutational burden (TMB), which leverages algorithmic filtering of germline variants, maintains clinical validity across ancestries without necessitating germline sequencing.
More Related Videos
07:15Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
Published on: January 16, 2019
10:41Wild-type Blocking PCR Combined with Direct Sequencing as a Highly Sensitive Method for Detection of Low-Frequency Somatic Mutations
Published on: March 29, 2017